Joint Press Release
Former Fred Hutch Tech Transfer V.P. Joins Seattle Cancer-Fighting Startup SEngine Precision Medicine as Chief Business Officer
Personalized Oncology Screening Results Validated in Method Developed by Seattle Cancer Research Organizations
SEngine + Fred Hutch
SEngine Precision Medicine Signs New Licensing Agreement with Fred Hutchinson Cancer Research Center
There are hundreds of drugs that treat cancer, and every patient reacts differently to each of them. That means doctors are often left in the dark when choosing which treatment to give a patient and patients often don’t get the most effective treatment for them.